Sjögren's disease & overlap diseases
Anti-PM-Scl antibodies–positive patients encompass three different groups with distinct prognoses
Authors' conclusion
Anti-PM-Scl-Abs associated auto-immune diseases are segregated into three subgroups with distinct clinical phenotype and outcomes. Skin thickening and NSIP are determinant predictors in segregation of theses populations.
Study context
- Population
- Consecutive patients (2011 to 2021) testing positive for anti-PM-Scl antibodies in a context of CTD, four hospitals129 included in clustering
- Participants
- 142 patients
- Exposure
- Cluster 1 vs Cluster 2 vs Cluster 3
- Cluster 1n = 47
- Cluster 2n = 36
- Cluster 3n = 46
- Outcome
- Homogeneous subgroups (clusters) by clinico-biological phenotype from features recorded in the first year of follow-up
- Follow-up
- First year
Methodological detailsmulticentre (four hospitals), consecutive patients, unsupervised multiple correspondence analysis, hierarchical clustering analysis
- Multicentre (four hospitals)
- Consecutive patients
- Unsupervised multiple correspondence analysis
- Hierarchical clustering analysis
Main finding
As reported in the abstract
Clusters of anti-PM-Scl-Abs positive patients
- Three clusters identified
- Cluster 1: more likely to develop progressive fibrosing ILD
- Cluster 2: increased risk of relapse; ILD with good functional outcome
- Cluster 3: predominant or isolated musculoskeletal involvement, frequently matching UCTD criteria
- Muscle involvement, though very frequent, less discriminating than skin thickening and ILD pattern for classifying patients
Observational data: associations, not effects.
Original publication
Anti-PM-Scl antibodies–positive patients encompass three different groups with distinct prognoses. Rheumatology (Oxford). Published 5 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →